Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.69 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA4 | P22748 | 3/20 | 0.69 |
| ▸ | CA6 | P23280 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | CA9 | Q16790 | 3/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.69 |
| ▸ | TPMT | P51580 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.60 |
| ▸ | TUBB | P07437 | 1/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isovanillic Acid SCHEMBL29883459 | 0.98 | HTT (0.72) | HTTCA12CA1CA2CA4 | |
| Isovanillic Acid SCHEMBL180473 | 0.98 | HTT (0.72) | HTTCA12CA1CA2CA4 | |
| Vanillic Acid SCHEMBL8853983 | 0.85 | HTT (0.96) | HTTCA12CA1CA2CA4 | |
| SCHEMBL27575811 | 0.84 | TUBB4A (0.80) | HTTLMNARAB9ATUBB4ATUBB | |
| SCHEMBL7820973 | 0.83 | MEN1 (0.59) | HTTCA12CA1CA2CA4 | |
| Vanillic Acid SCHEMBL9711598 | 0.82 | HTT (1.00) | HTTCA12CA1CA2CA4 | |
| Vanillic Acid SCHEMBL26179 | 0.82 | HTT (1.00) | HTTCA12CA1CA2CA4 | |
| SCHEMBL29757916 | 0.82 | TUBB1 (0.62) | HTTLMNARAB9ATUBB4ATUBB | |
| Water SCHEMBL28758018 | 0.82 | TUBB4A (0.77) | HTTLMNARAB9ATUBB4ATUBB | |
| Vanillic Acid SCHEMBL29378740 | 0.82 | HTT (1.00) | HTTCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2015647-A2 | IRON COMPLEX FOR USE IN THE TREATMENT AND/OR PREVENTION OF NUTRITIONAL DISORDERS | UNILEVER N.V. (NL) | 2009-01-21 | — | — | EP | disclosed |
| WO-2006037449-A2 | IRON COMPLEX FOR USE IN THE TREATMENT AND/OR PREVENTION OF NUTRITIONAL DISORDERS | UNILEVER N.V. (NL) | 2006-04-13 | — | — | WO | disclosed |
| US-20060078594-A1 | Iron complex | CONOPCO, INC., D/B/A UNILEVER | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060078594-A1 | Iron complex | SLC40A1, FECH, TFRC | HTT 535/4885CA12 2678/4885CA1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.